window.addEventListener('load', function() { if (window.location.href.indexOf('/cart') != -1) { gtag('event', 'conversion', { 'send_to': 'AW-933941381/NlyyCLXdjc0DEIWhq70D' }); } });

Meloxicam Ilium Dog Oral *Prescription required



Meloxicam Ilium Dog Oral

Description: An aqueous, oral suspension for oral administration. Active Ingredients: 1.5 mg meloxicam per mL. Action:  Meloxicam is a non-steroidal anti-inflammatory compound of the oxicam group which acts by inhibition of prostaglandin synthesis. Meloxicam exerts anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It inhibits leucocyte infiltration into the inflamed tissue and prevents bone and cartilage destruction. To a minor extent it also inhibits collagen induced thrombocyte aggregation. Indication:  A non-steroidal anti-inflammatory drug (NSAID) for use in dogs. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as disco-spondylosis, arthropathy and soft tissue injuries.  Contraindications:  Do not administer to pregnant or lactating bitches in the last third of the pregnancy. As for all NSAIDs, use in animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided, careful clinical management may be required. The use of product is contraindicated in animals suffering from cardiac, hepatic or clinical renal disease. This is also the case where there is possibility of gastro-intestinal ulceration  haemorrhagic disorder or individual hypersensitivity to the product. Meloxicam Oral Suspension should not be administered concurrently with steroidal or other nonsteroidal anti-inflammatory drugs, aminoglycoside antibiotics or anticoagulant agents. Pre-treatment with
anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatmentfree period with such drugs should be observed for at least 24 hours before commencement with Meloxicam Oral Suspension. The treatment-free period, however, should take into account the pharmacokinetic properties of the drug used previously. Toxicity/Overdose/Antidote:  In case of over-dosing, a symptomatic treatment should be initiated. Dosage:  Shake well before use. Should be administered mixed with food. On the first day of treatment a single dose of 0.2mg/kg b.w.(2 drops/kg) should be given. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at maintenance dose of 0.1mg/kg b.w. (1 drops/kg).  Side effects:  Typical adverse reactions of NSAIDs may occur (particularly within the first 5-14 days of treatment). These may include loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy. Gastrointestinal side effects are in most cases transient and disappear following termination of treatment, but in rare cases may be serious. If gastro-intestinal side effects are persistent or of severity, treatment should be discontinued. 
Presentation:  Presented in 10ml, 50ml and 100ml plastic squeeze dropper tubes with a measuring syringe in pack.